Swiss National Bank Decreases Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Swiss National Bank lowered its position in Eli Lilly and Company (NYSE:LLY) by 2.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,523,290 shares of the company’s stock after selling 72,000 shares during the period. Eli Lilly and Company makes up about 1.1% of Swiss National Bank’s portfolio, making the stock its 11th largest position. Swiss National Bank owned approximately 0.27% of Eli Lilly and Company worth $1,470,876,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the company. Fisher Asset Management LLC grew its stake in Eli Lilly and Company by 2.0% during the 4th quarter. Fisher Asset Management LLC now owns 4,544,585 shares of the company’s stock worth $2,649,130,000 after buying an additional 87,511 shares during the last quarter. LGT Fund Management Co Ltd. grew its stake in shares of Eli Lilly and Company by 4.4% during the fourth quarter. LGT Fund Management Co Ltd. now owns 9,520 shares of the company’s stock worth $5,530,000 after acquiring an additional 400 shares during the last quarter. Heritage Wealth Management LLC acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $1,298,000. Robertson Stephens Wealth Management LLC raised its position in shares of Eli Lilly and Company by 30.6% in the 4th quarter. Robertson Stephens Wealth Management LLC now owns 4,145 shares of the company’s stock valued at $2,416,000 after purchasing an additional 971 shares during the last quarter. Finally, McIlrath & Eck LLC boosted its stake in Eli Lilly and Company by 16.5% in the 4th quarter. McIlrath & Eck LLC now owns 465 shares of the company’s stock worth $271,000 after purchasing an additional 66 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on LLY shares. BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research note on Wednesday. The Goldman Sachs Group upped their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday. Finally, Morgan Stanley lifted their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Stock Performance

NYSE LLY traded down $18.26 during mid-day trading on Thursday, reaching $758.49. 1,584,206 shares of the stock were exchanged, compared to its average volume of 3,049,690. The business’s 50 day moving average is $762.03 and its 200-day moving average is $669.96. The company has a market capitalization of $720.69 billion, a P/E ratio of 111.71, a P/E/G ratio of 1.58 and a beta of 0.37. Eli Lilly and Company has a 1 year low of $414.31 and a 1 year high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 59.28% and a net margin of 17.08%. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.62 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 13.5 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.